Program
Tafamidis Meglumine Soft Capsules
Its studies are mostly in Amyloid Neuropathies, Familial, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 11 open or running | phase 4since Apr 8, 2025 | Apr 8, 2025 | Jan 2028phase 4 · NCT06940336 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 8, 2025First study: phase 4 study in Amyloid Neuropathies, FamilialFirst studyNCT06940336 · 15 planned · China
Ahead
- Jan 2028Primary completion: phase 4 study in Amyloid Neuropathies, FamilialNCT06940336
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06940336Amyloid Neuropathies, Familial · China | 4 | Recruiting | Jan 2028 | 15 |
How it is read
Names in the registry
- “Tafamidis Meglumine Soft Capsules”, 1 entry
Conditions, from the studies’ own filings
- Amyloid Neuropathies, Familial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.